4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives $28.70 Consensus PT from Analysts

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) have earned a consensus rating of “Moderate Buy” from the eleven brokerages that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation and eight have given a buy recommendation to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $28.70.

Several research analysts recently commented on the company. Morgan Stanley raised 4D Molecular Therapeutics from an “underweight” rating to an “equal weight” rating in a research report on Friday, November 7th. Roth Capital reduced their price objective on shares of 4D Molecular Therapeutics from $44.00 to $38.00 and set a “buy” rating for the company in a report on Tuesday, August 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research report on Wednesday, October 8th. Wall Street Zen raised shares of 4D Molecular Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Finally, Leerink Partners restated an “outperform” rating and set a $17.00 price target on shares of 4D Molecular Therapeutics in a research note on Friday, October 31st.

Insider Buying and Selling

In other 4D Molecular Therapeutics news, insider Scott Bizily sold 2,678 shares of the company’s stock in a transaction on Friday, October 24th. The stock was sold at an average price of $12.00, for a total value of $32,136.00. Following the sale, the insider directly owned 3,594 shares in the company, valued at $43,128. This represents a 42.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Over the last quarter, insiders sold 10,763 shares of company stock valued at $109,415. 9.60% of the stock is owned by insiders.

Institutional Investors Weigh In On 4D Molecular Therapeutics

A number of hedge funds have recently made changes to their positions in FDMT. BVF Inc. IL boosted its position in 4D Molecular Therapeutics by 1.5% in the second quarter. BVF Inc. IL now owns 4,629,289 shares of the company’s stock valued at $17,175,000 after buying an additional 68,000 shares in the last quarter. Federated Hermes Inc. raised its stake in shares of 4D Molecular Therapeutics by 33.4% in the second quarter. Federated Hermes Inc. now owns 1,667,338 shares of the company’s stock valued at $6,186,000 after acquiring an additional 417,157 shares during the last quarter. Millennium Management LLC boosted its holdings in shares of 4D Molecular Therapeutics by 15.0% in the 1st quarter. Millennium Management LLC now owns 1,633,987 shares of the company’s stock worth $5,278,000 after acquiring an additional 213,264 shares in the last quarter. Armistice Capital LLC boosted its holdings in shares of 4D Molecular Therapeutics by 265.3% in the 3rd quarter. Armistice Capital LLC now owns 1,096,000 shares of the company’s stock worth $9,524,000 after acquiring an additional 796,000 shares in the last quarter. Finally, Assenagon Asset Management S.A. grew its position in 4D Molecular Therapeutics by 2.3% during the 3rd quarter. Assenagon Asset Management S.A. now owns 663,657 shares of the company’s stock worth $5,767,000 after acquiring an additional 14,832 shares during the last quarter. Institutional investors and hedge funds own 99.27% of the company’s stock.

4D Molecular Therapeutics Stock Up 0.5%

FDMT stock opened at $10.89 on Friday. 4D Molecular Therapeutics has a twelve month low of $2.23 and a twelve month high of $12.34. The company has a market cap of $622.20 million, a PE ratio of -2.90 and a beta of 2.96. The business’s 50-day simple moving average is $9.77 and its 200 day simple moving average is $6.61.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its quarterly earnings results on Monday, November 10th. The company reported ($1.01) EPS for the quarter, beating the consensus estimate of ($1.02) by $0.01. 4D Molecular Therapeutics had a negative return on equity of 47.27% and a negative net margin of 174,314.17%.The firm had revenue of $0.09 million during the quarter, compared to analysts’ expectations of $0.40 million. On average, equities research analysts anticipate that 4D Molecular Therapeutics will post -2.84 EPS for the current year.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.